- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03783884
Een protocol waarin tijdelijke transveneuze diafragmastimulatie wordt vergeleken met de zorgstandaard voor het ontwennen van mechanische beademing (RESCUE 3)
Een gerandomiseerd, gecontroleerd, open-label, multicenter klinisch onderzoek om de veilige en effectieve werking van het longpacer-membraanstimulatietherapiesysteem te evalueren bij patiënten die niet zijn afgebouwd van mechanische beademing.
This clinical investigation is an open-label, multi-center, randomized clinical trial (RCT) to demonstrate the safety and effective performance of the Lungpacer DPTS (plus standard of care) as compared to Control (standard of care only) in patients aged 18 years or older who are receiving mechanical ventilation. Eligible Subjects will have received mechanical ventilation for ≥96 hours (4 days) and have failed two weaning attempts.
The goal or outcome is to show a numerically greater proportion of subjects weaned in the Treatment (Lungpacer DPTS) group as compared to the Control group.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
The intended patient population is applicable for Lungpacer Diaphragm Pacing Therapy (DPT) because there are no noninvasive alternative treatments for patients who are difficult to wean from MV (i.e., ≥96 hours (4 days) on MV) or who have required prolonged MV (>7 days). The intended patient population includes approximately one-third of all patients on mechanical ventilation. Under standard of care, approximately 50% of these patients will recover from mechanical ventilation (Jung, 2016). Standard of care involves daily weaning attempts, known as Spontaneous Breathing Trials (SBTs) or Ventilator Liberation Trials (VLTs) that are intended to encourage diaphragm use and strengthening over time.Therefore, Lungpacer DPT efficacy evaluation must be compared to standard of care in a Control group. Lack of recovery from mechanical ventilation may be due to the inability of a patient to participate in VLTs or weaning attempts, due to extensive diaphragm weakness or sedation, the inability of VLTs to induce sufficient diaphragm strengthening, or co-morbidities that prevent recovery.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Berlin, Duitsland, 10117
- Berlin Charite Mitte
-
Essen, Duitsland, 45276
- KEM Essen
-
Löwenstein, Duitsland, 74245
- SLK Löwenstein
-
Nuremberg, Duitsland, 90419
- Nürnberg Klinikum Nord
-
Schmallenberg, Duitsland, 57392
- FKKG Schmallenberg
-
Solingen, Duitsland, 42699
- Solingen Krankenhaus Bethanien
-
-
Mecklenburg-Vorpommern
-
Greifswald, Mecklenburg-Vorpommern, Duitsland, 17475
- Universitätsmedizin Greifswald
-
-
-
-
-
Angers, Frankrijk, 49933
- CHU Angers
-
Montpellier, Frankrijk, 34295
- CHU Montpellier
-
Paris, Frankrijk, 75651
- Hôpital La Pitié-Salpêtrière
-
Strasbourg, Frankrijk, 67091
- CHU Strasbourg
-
-
-
-
California
-
Stanford, California, Verenigde Staten, 94305
- Stanford University Medical Center
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- University of Colorado Anschutz Medical Campus
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32610
- University of Florida, Shands
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60612
- Rush University Medical Center
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern University Feinberg School of Medicine
-
Chicago, Illinois, Verenigde Staten, 60612
- U of Illinois at Chicago
-
Hines, Illinois, Verenigde Staten, 60141
- Edward Hines VA Hospital
-
Maywood, Illinois, Verenigde Staten, 60153
- Loyola University Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202
- Indiana University Health Methodist Hospital
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40202
- University of Louisville
-
-
Massachusetts
-
Burlington, Massachusetts, Verenigde Staten, 01805
- Lahey Hospital and Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Minneapolis Heart Institute Foundation
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68124
- CHI Health Creighton University Medical Center - Bergan Mercy
-
-
New Jersey
-
Englewood, New Jersey, Verenigde Staten, 07631
- Englewood Hospital Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45267
- University of Cincinnati
-
Cleveland, Ohio, Verenigde Staten, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Verenigde Staten, 43210
- Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19140
- Temple University Hospital
-
-
Rhode Island
-
Warwick, Rhode Island, Verenigde Staten, 02886
- Kent County Memorial Hospital
-
-
South Carolina
-
Columbia, South Carolina, Verenigde Staten, 29203
- Prisma Health Baptist Hospital
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75390
- University of Texas Southwestern, Zale Lipshy Hospital
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84132
- University of Utah
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Are 18 years or older, and,
- Have been mechanically ventilated for ≥96 hours (4 days), and,
- Have satisfied the Readiness-to-Wean criteria, and,
- Have failed at least 2 weaning attempts (that were conducted at least 48 hours after initiation of MV, and, that were conducted on different calendar days, and, at least one of which was the protocol-specific Ventilator Liberation Trial).
Exclusion Criteria:
- Maximal Inspiratory Pressure (MIP) (absolute value) >50 cm H2O;
- Invasive mechanical ventilation >90 days;
- Currently on extracorporeal membrane oxygenation (ECMO);
- Weaning failure due to hypervolemia;
- Medical history (including imaging) or known anatomy that prevents percutaneous insertion of the Catheter into the intended thoracic vein on the left side.
- Clinically overt congestive heart failure that is preventing weaning;
- Currently being treated with neuromuscular blockade;
- Pre-existing neurological, neuromuscular or muscular disorder that could affect the respiratory muscles;
- Pre-existing severe chronic pulmonary fibrosis;
- Pleural effusions occupying greater than one third of the pleural space on either side;
- BMI >45 kg/m2;
- Known or suspected phrenic nerve paralysis;
- Any electrical device (implanted or external) that may be prone to interaction with, or interference from the Lungpacer DPTS including neurological pacing/stimulator devices, cardiac pacemakers and defibrillators;
- Current hemodynamic instability, sepsis or septic shock;
- Prior bacteremia reported within the last 48 hours;
- Anticipating withdrawal of life support and/or shift to palliation as the goal of care;
- Known or suspected to be pregnant or lactating;
- Currently being treated in another clinical trial studying an experimental treatment that could affect the study primary outcome.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Treatment
Subject receives Lungpacer Catheter for transvenous phrenic nerve stimulation to deliver Diaphragm Pacing Therapy Sessions. DPT sessions are 6 sets of 10, delivered twice daily, for a total of 120 stimulation reps per day, plus standard of care for weaning from mechanical ventilation. |
Transvenous phrenic nerve stimulation to induce diaphragm contraction.
Andere namen:
|
|
Geen tussenkomst: Control
Subject does not receive Lungpacer Catheter or DPT. Subject receives only Standard of care for weaning from mechanical ventilation. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Successful Weaning
Tijdsspanne: Through Day 30
|
Cumulative percentage of subjects successfully weaned by Day 30. |
Through Day 30
|
|
Adverse Event Profile
Tijdsspanne: 30 days
|
Characterize the adverse event profile to support an observed consistent risk profile for subjects randomized to Treatment compared to subjects randomized to Control. Percentage of subjects with adverse events (AE) and serious adverse events (SAE) were summarized for the Treatment group and the Control group by system organ class (SOC) and lower level term. No formal statistical hypothesis test or criterion for the primary safety endpoint was defined. |
30 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Days on Mechanical Ventilation (MV)
Tijdsspanne: Successful weaning or Day 30
|
The average days on mechanical ventilation from Day 1 to removal from MV associated with successful weaning or Day 30, whichever comes first, will be statistically significantly smaller for subjects randomized to Treatment as compared to subjects randomized to Control. |
Successful weaning or Day 30
|
|
Maximal Inspiratory Pressure (MIP) Change
Tijdsspanne: Baseline last available measure through Day 30.
|
The mean improvement in inspiratory muscle strength as shown by the change in Maximal Inspiratory Pressure (MIP) from randomization to last available measure in subjects randomized to Treatment is superior to that in subjects randomized to Control. |
Baseline last available measure through Day 30.
|
|
Rapid Shallow Breathing Index (RSBI) Change
Tijdsspanne: Baseline to last available measure through Day 30.
|
To determine change in Rapid Shallow Breathing Index (RSBI) from randomization to last available measure in subjects randomized to Treatment as compared to Control. RSBI measures the ratio of the respiratory rate to Tidal Volume in breaths/min/L and is commonly used as an index for weaning success. A reduction in RSBI is considered as clinical improvement. |
Baseline to last available measure through Day 30.
|
|
Survival
Tijdsspanne: 30 days
|
Cumulative percentage of subjects who survived through Day 30. |
30 days
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Re-instatements of MV (After Successful Weaning) Through Day 30.
Tijdsspanne: Through Day 30.
|
Assessment of re-instatements of MV in subjects who were successful weaned through Day 30 in the Treatment group as compared to the Control group. |
Through Day 30.
|
|
Tracheotomy After Randomization
Tijdsspanne: Through 30 days
|
Assessment of percentage of subjects after randomization to Day 30 that required tracheostomy in the Treatment group as compared to the Control group. |
Through 30 days
|
|
ICU Discharges to Day 30.
Tijdsspanne: through 30 days
|
Assessment of ICU discharges to Day 30 in the Treatment group as compared to the Control group. |
through 30 days
|
|
Hospital Discharges to Day 30.
Tijdsspanne: through 30 days
|
Assessment of hospital admissions and discharges to Day 30 in the Treatment group as compared to the Control group. |
through 30 days
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- P-300
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Only investigators participating in this clinical trial will be able to see final de-identified participant data at the completion of the study.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .